Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 10/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 10/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776374 | 0.90 | TSHR (0.46) | BRAFTSHRTP53GAASMN1; SMN2 | |
| SCHEMBL16776366 | 0.88 | PHGDH (0.40) | PRMT5WDR77 | |
| SCHEMBL16776380 | 0.83 | BRAF (0.46) | BRAFBRD4CREBBPLIMK2TP53 | |
| SCHEMBL16776372 | 0.82 | CNR2 (0.51) | CNR2TP53GAASMN1; SMN2GRM5 | |
| SCHEMBL16776381 | 0.82 | ABL1 (0.36) | CNR2SMN1; SMN2 | |
| SCHEMBL16776375 | 0.82 | FAAH (0.38) | BRAFCNR2TP53GAASMN1; SMN2 | |
| SCHEMBL19670426 | 0.81 | TP53 (0.39) | BRAFTSHRCNR2TP53GAA | |
| SCHEMBL16776373 | 0.80 | FGFR4 (0.40) | BRAFLIMK2CNR2GRM5 | |
| SCHEMBL16785644 | 0.80 | TSHR (0.46) | TSHRTP53GAASMN1; SMN2 | |
| SCHEMBL16776378 | 0.78 | P2RY1 (0.39) | BRAFCNR2TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | BRAF 3419/4885PRMT5 209/4885WDR77 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.